ROLE OF CANCER STEM CELLS IN PEDIATRIC MEDULLOBLASTOMA CARCINOGENESIS
https://doi.org/10.29235/1814-6023-2018-15-1-99-107
Abstract
Medulloblastoma refers to the group of malignant brain tumors of embryonic origin. It is the most common malignant primary tumor in children. Present-day technologies of medulloblastoma treatment include surgical methods combined with radio-, chemo- and adjuvant therapies allowed one to bring a vast improvement in results of tumor treatment. However, the survival rates are still far from ideal. Difficulties of treatment consist in tumor cell heterogeneity – various cells exhibit different properties and levels of sensitivity to chemotherapeutic drugs. Cell heterogeneity is an unsolved problem in oncology. Among the population of cancer cells is a small group of cancer stem cells, which is revealed to be the main element in initiation, maintenance and progression of a tumor growth. Cancer stem cell key properties are the unrestricted ability to self-renewal, migration within brain parenchyma, hypoxic type of metabolism and localization in the most hypoxic regions of tumor. We analyzed all literature data about medulloblastoma cancer stem cells in children, their main markers and properties, which allow them to express chemo- and radioresistance.
About the Authors
Elena Y. Chernysh
Republican Research and Clinical Center of Neurology and Neurosurgery
Russian Federation
Russian Federation
Researcher
24, F. Skoriny Str., 220114, Minsk
Larisa N. Nikolaevich
Institute of Physiology of the National Academy of Sciences of Belarus
Russian Federation
Russian Federation
Ph. D. (Biol.), Assistant Professor, Head of the Laboratory
28, Akademicheskaya Str., 220072, Minsk
Ludmila P. Parkhach
Republican Research and Clinical Center of Neurology and Neurosurgery
Russian Federation
Russian Federation
Ph. D. (Biol.), Assistant Professor, Scientific Secretary
24, F. Skoriny Str., 220114, Minsk
References
1. Ryshova M. V., Shishkina L. V. Comparative analysis of molecular-genetical aberrations in medulloblastomas. Voprosy neirohirurgii imeni N. N. Burdenko [Burdenko’s Journal of Neurosurgery], 2012, vol. 76, no. 6, pp. 66–72 (in Russian).
2. Semenova V. M., Egorova D. M., Stajni L. P. Possibilities of cultural method in investigation of cancer stem cells biological treats in malignant brain gliomas. Kletochnye kul’tury: informatsionnyi byulleten’[Cell cultures: newsletter], 2016, iss. 32, pp. 62–81 (in Russian).
3. Li Z. CD133: a stem cell biomarker and beyond. Experimental Hematology and Oncology, 2013, vol. 2, no. 1, p. 17. DOI: 10.1186/2162-3619-2-17
4. Read T.-A., Fogarty M. P., Markant S. L., McLendon R. E., Wei Zh., Ellison D. W., Febbo Ph. G., Wechsler-Reya R. J. Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma. Cancer Cell, 2009, vol. 15, no. 2, pp. 135–147. DOI: 10.1016/j.ccr.2008.12.016
5. Friedman G. K., Moore B. P., Nan L., Kelly V. M., Etminan T., Langford C. P., Xu H., Han X., Markert J. M., Beierle E. A., Gillespie G. Y. Pediatric medulloblastoma xenografts including molecular subgroup 3 and CD133+ and CD15+ cells are sensitive to killing by oncolytic herpes simplex viruses. Neuro-Oncology, 2016, vol. 18, no. 2, pp. 227–235. DOI: 10.1093/ neuonc/nov123
6. Kuppner M. C., Van Meir E., Gauthier T., Hamou M.-F., de Tribolet N. Differential expression of the CD44 molecule in human brain tumors. International Journal of Cancer, 1992, vol. 50, no. 4, pp. 572–577. DOI: 10.1002/ijc.2910500414
7. Liu J., Chi N., Zhang J. Y., Zhu W., Bian Y. S., Chen H. G. Isolation and characterization of cancer stem cells from medulloblastoma. Genetics and Molecular Research, 2015, vol. 14, no. 2, pp. 3355–3361. DOI: 10.4238/2015.april.13.15
8. Morrison L. C., McClelland R., Aiken Ch., Bridges M., Liang L., Wang X., di Curzio D., del Bigio M. R., Taylor M. D., Werbowetski-OgilvieT. E. Deconstruction of medulloblastoma cellular heterogeneity reveals differences between the most highly invasive and self-renewing phenotype. Neoplasia, 2013, vol. 15, no. 4, pp. 384–398. DOI: 10.1593/neo.13148
9. Mack S. C., Hubert Ch. G., Miller T. E., Taylor M. D., Rich J. N. An epigenetic gateway to brain tumor cell identity. Nature Neuroscience, 2016, vol. 19, no. 1, pp. 10–19. DOI: 10.1038/nn.4190
10. Schonberg D. L., Lubelski D., Miller T. E., Rich J. N. Brain tumor stem cells: molecular characteristics and their impact on therapy. Molecular Aspects of Medicine, 2014, vol. 39, pp. 82–101. DOI: 10.1016/j.mam.2013.06.004
11. Rodini C. O., Suzuki D. E., Nakahata A. M., Pereira M. C. L., Janjoppi L., Toledo S. R. C., Okamoto O. K. Aberrant signaling pathways in medulloblastomas: a stem cell connection. Arquivos de Neuro-Psiquiatria, 2010, vol. 68, no. 6, pp. 947–952. DOI: 10.1590/s0004-282x2010000600021
12. Diaz A., Leon K. Therapeutic approaches to target cancer stem cells. Cancers, 2011, vol. 3, no. 4, pp. 3331–3352. DOI: 10.3390/cancers3033331
13. Castriconi R., Dondero A., Negri F., Bellora F., Nozza P., Carnemolla B., Raso A., Moretta L., Moretta A., Bottino C. Both CD133+ and CD133– medulloblastoma cell lines express ligands for triggering NK receptors and are susceptible to NKmediated cytotoxicity. European Journal of Immunology, 2007, vol. 37, no. 11, pp. 3190–3196. DOI: 10.1002/eji.200737546
14. Huang G.-H., Xu Q.-F., Cui Y.-H., Li N., Bian X.-W., LvSh.-Q. Medulloblastoma stem cells: Promising targets in medulloblastoma therapy. Cancer Science, 2016, vol. 107, no. 5, pp. 583–589. DOI: 10.1111/cas.12925
15. Heppner G. H. Tumor heterogeneity. Cancer Research, 1984, vol. 44, no. 6, pp. 2259–2265.
16. Visvader J. E. Cells of origin in cancer. Nature, 2011, vol. 469, no. 7330, pp. 314–322. DOI: 10.1038/nature09781
17. Inda M.-d.-M., Bonavia R., Mukasa A., Narita Y., Sah D. W. Y., Vandenberg S., Brennan C., Johns T. G., Bachoo R., Hadwiger P., Tan P., DePinho R. A., Cavenee W., Furnari F. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes and Development, 2010, vol. 24, no. 16, pp. 1731–1745. DOI: 10.1101/ gad.1890510
18. Snijder B., Pelkmans L. Origins of regulated cell-to-cell variability. Nature Reviews Molecular Cell Biology, 2011, vol. 12, no. 2, pp. 119–125. DOI: 10.1038/nrm3044
19. Marusyk F., Polak K. Tumor heterogeneity: causes and consequences. Biochimica et Biophysica Acta (BBA) – Reviews on Cancer, 2010, vol. 1805, no. 1, pp. 105–117. DOI: 10.1016/j.bbcan.2009.11.002
20. Pietras A. Cancer stem cells in tumor heterogeneity. Advances in Cancer Research, 2011, vol. 112, pp. 255–281. DOI: 10.1016/B978-0-12-387688-1.00009-0
21. Ruijter E. T., van de Kaa C. A., Schalken J. A., Debruyne F. M., Ruiter D. J. Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications. Journal of Pathology, 1996, vol. 180, no. 3, pp. 295–299. DOI: 10.1002/(SICI)1096-9896(199611)180:33.0.CO;2-W
22. Maley С. C., Galipeau P. C., Finley J. C., Wongsurawat V. J., Li X., Sanchez C. A., Paulson T. G., Blount P. L., Risques R.-A., Rabinovitch P. S., Reid B. J. Genetic clonal diversity predicts progression to esophageal adenocartinoma. Nature Genetics, 2006, vol. 38, no. 4, pp. 468–473. DOI: 10.1038/ng1768
23. Nemcova M. V. Cell heterogeneity in tumor. Medicinskaya genetika [Medical genetics], 2012, vol. 11, no. 11 (125), pp. 3–12 (in Russian).
24. Gatenby R. A., Silva A. S., Gilities R. J., Frieden B. R. Adaptive therapy. Сancer Research, 2009, vol. 69, no. 11, pp. 4894–4903. DOI: 10.1158/0008-5472.can-08-3658
25. Nikilaevich L. N., Talabaev M. V. Innovative scientific methods of improvement the effectiveness of glioma diagnostics and treatment. Nauka, innovatsii, investitsii: sbornik materialov 2-go Belorussko-Latviiskogo foruma (11–12 dekabrya 2014 g.) [Science, innovations, investments: a collection of materials of the 2nd Belarusian-Latvian Forum (December 11–12, 2014)]. Minsk, 2014, pp. 49–51 (in Russian).
26. Nikolaevich L. N., Zalutsky I. V., Adekenov S. M. Investigation the exposure to the drug “Arglabin” on the glial tumor. Rossijski bioterapevticheskii zhurnal [Russian biotherapeutical journal], 2014, vol. 13, no. 1, p. 114 (in Russian).
27. Nikolaevich L. N., Zalutsky I. V., Talabaev M. V., Adekenov S. M., Sirota V. B. Sensitivity of clonogenic human medulloblastoma tumor cells to influence of antitumoral preparation «Arglabin»: innovative approach. Science. Innovation. Production: Proceedings of the 3rd Belarus-Korea Forum (October 16–17, 2014). Minsk, 2014, pp. 7–8.
Review
For citations:
Chernysh E.Y., Nikolaevich L.N., Parkhach L.P. ROLE OF CANCER STEM CELLS IN PEDIATRIC MEDULLOBLASTOMA CARCINOGENESIS. Proceedings of the National Academy of Sciences of Belarus, Medical series. 2018;15(1):99-107. (In Russ.) https://doi.org/10.29235/1814-6023-2018-15-1-99-107
Views: 505
Email this article 